Skip to main content

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an important step toward making the vaccine available in one of the countries most affected by chikungunya. Brazil accounts for a substantial proportion of reported chikungunya cases and related deaths globally, underscoring the continued need for effective preventive measures against the disease. Paul Chaplin, President & CEO of Bavarian Nordic, said:...

Continue reading

Power Solutions International Sets Date for Second Quarter 2026 Earnings Release and Conference Call

WOOD DALE, Ill., July 13, 2026 (GLOBE NEWSWIRE) — Power Solutions International, Inc. (Nasdaq: PSIX), a leader in the design, engineering and manufacture of emission-certified engines and power systems, plans to conduct a conference call to discuss its second quarter 2026 results and business outlook on Thursday, August 6, 2026, at 5:00 p.m. Eastern time. After the close of the market on August 6 and prior to the conference call, Power Solutions International (“PSI”) will issue a copy of the earnings press release via Globe Newswire. The press release may also be viewed on PSI’s website at https://investors.psiengines.com/press-releases. To listen to the conference call, please register at the following link: https://edge.media-server.com/mmc/p/eps9ifcs. General listeners may access the live audio-only webcast at the...

Continue reading

Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in Canaccord Genuity’s 46th annual Growth Conference, taking place in Boston, including a fireside chat on Tuesday, August 11, at 8:00 a.m. EDT. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event. About Omada Health Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today’s healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity,...

Continue reading

T3 Defense Subsidiary Rimon Delivers $1.1 Million Order with Major Israeli Defense Customer for Advanced Elevated Battlefield Lighting Systems

Highlights Growing Demand for Rapid-Deployment Illumination Solutions Across Border Security, Perimeter Defense, and Surveillance in Forward Operating Environments NEW YORK and NETANYA, Israel, July 13, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses, today announced that its wholly owned subsidiary, Rimon Agencies Ltd. (“Rimon”), completed the delivery of a $1.1 million order for Yam-Or portable elevated lighting systems to a major Israeli defense customer. The order was structured across two delivery phases and executed entirely through Rimon’s in-house engineering and manufacturing operation. Rimon delivered both phases on schedule and in full compliance with customer specifications, demonstrating its capacity...

Continue reading

Workhorse Appoints Jody Davis as Chief Financial Officer

Seasoned capital markets and manufacturing finance executive succeeds current CFO Bob Ginnan who is retiringJody Davis, Chief Financial Officer at WorkhorseJody Davis joins Workhorse as CFO, replacing current CFO Bob Ginnan, who is retiring.DETROIT, July 13, 2026 (GLOBE NEWSWIRE) — Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse”), a North American OEM and provider of all-electric trucks, step vans, shuttles and buses, today announced the appointment of Jody Davis as Chief Financial Officer (CFO), replacing current CFO Bob Ginnan, who is retiring. Davis is a finance executive with approximately 15 years of finance leadership experience across manufacturing, energy storage, aerospace, and technology companies, with a track record of closing large capital rounds and guiding development-stage businesses into full production....

Continue reading

Chatham Lodging Trust Announces Second Quarter 2026 Earnings Call to be Held on Tuesday, August 4, 2026

For Immediate ReleaseContact:    Chris Daly                                                             Dennis Craven                  Daly Gray Public Relations                                  Chatham Lodging Trust                  (Media)                                                                 (Company)                  chris@dalygray.com                                             dcraven@cl-trust.com                  (703) 864-5553                                                     (561) 227-1386           WEST PALM BEACH, Fla., July 13, 2026 (GLOBE NEWSWIRE) — Chatham Lodging Trust (NYSE: CLDT), a lodging real estate investment trust (REIT) that invests in upscale, extended-stay hotels and premium-branded, select-service hotels, today announced that it will report second quarter 2026 financial results on Tuesday,...

Continue reading

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today provided...

Continue reading

RedCloud unveils CORE, the Operating Environment That Will Unify Trade Intelligence and Action, Built on $6.9 Billion Data Foundation

CORE, the Compounding Operating Runtime Engine, is near completion as the final piece of enabling technology behind RedAI’s Specialist Agents — with the aim of pairing with RAID to predict, recommend and complete trading outcomes for customers London, July 13, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), the company building intelligent infrastructure for global trade, today announced CORE — the trade execution engine expected to be the final foundational enabling technology of its RedAI infrastructure and be the centrepiece of a launch planned for August 2026. CORE is the second enabling technology alongside RAID (Realtime AI for Distribution), together, upon complete development and implementation, are expected to drive a future of autonomous trade within the RedAI infrastructure. CORE...

Continue reading

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. Oral presentation by Principal Investigator Dr. Steven E. McKenzie highlighted CAD-1005 as the first randomized, blinded, placebo-controlled trial for Heparin-Induced Thrombocytopenia (HIT). Phase 2 data demonstrate an absolute reduction of more than 25% in thrombotic events, supporting the clinical advancement of this Phase 3-ready program. CAD-1005 targets a life-threatening immune-mediated clotting disorder, with an estimated $2 billion in peak annual revenue and no currently approved root-cause therapies.PARIS, July 13, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical...

Continue reading

Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call

DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.